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Abstract Cardiovascular disease (CVD) is the leading cause
of morbidity and mortality worldwide. New diagnostic and
therapeutic strategies are needed to mitigate this public health
issue. Advances in nanotechnology have generated innovative
strategies for diagnosis and therapy in a variety of diseases,
foremost in cancer. Based on these studies, a novel concept
referred to as nanomedical theranostics, or the combinatory
application of nanoparticulate agents to allow diagnostic
therapy, is being explored to enable image-guided, personal-
ized, or targeted treatment. Preclinically, theranostics have
been gradually applied to CVD with several interesting and
encouraging findings. This article summarizes studies and
challenges of nanotheranostic strategies in CVD. It also
evaluates nanotheranostic strategies that may potentially be
utilized to benefit patients.
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Introduction
Cardiovascular disease (CVD) is the most prevalent disease
in the United States, accounting for 1 out of 3 deaths in
2007, with an estimated cost of 286 billion US dollars [1•].
New diagnostic and therapeutic strategies are needed as
patients present themselves at late stages of disease or,
more commonly, after cardiovascular events. In addition,
subsets of patients do not respond to current therapeutic
methods [2].
An improved understanding of atherosclerosis, the
underlying cause of the majority of CVDs, has identified
several biological processes that aggravate this syndrome.
In the early stages of atherosclerosis, the endothelium, a
continuous layer of endothelial cells (ECs) lining the vessel
wall, starts—under influence of cardiovascular disease risk
factors such as hypertension, abnormal blood lipid levels or
smoking—to express high levels of adhesion molecules and
have increased cellular gaps. This initiates accumulation of
low-density lipoproteins (LDL) as well as activated macro-
phages in the subendothelial layer. In later stages, high
levels of extracellular proteinases, apoptotic cells, and
accumulating radicals contribute to the progression of
atherosclerotic plaques. As the plaque progresses,
hypoxia-driven angiogenesis triggers the formation of new
blood vessels. In the final stage of atherosclerosis, tissue
factors from plaques are exposed to blood and induce
thrombosis, resulting in clinical symptoms such as myo-
cardial infarction or stroke [3, 4•].
In biomedicine, nanoparticles, typically defined as
materials with at least one dimension of 100 nm or less,
have been exploited for both diagnostic and therapeutic
purposes [5]. Certain contrast agents and potent drugs may
exhibit a poor blood half-life and high systemic toxicity,
which can potentially be improved by their encapsulation
within nanoparticles. In addition, nanoparticles can increase
the effectiveness of many diagnostic or therapeutic agents.
Decorating nanoparticles with targeting molecules against
biomarkers of a disease facilitates their specific delivery
and accumulation within pathological tissue [6].
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Although the application of nanoparticles to diagnose
and treat atherosclerosis is a relatively young field, a
number of studies have shown its growing potential. In
atherosclerotic plaques, the high expression levels of certain
molecules, such as αvβ3-integrin on ECs, allow these cells
to be directly reached from the circulation and therefore to
be specifically targeted by nanoparticles [7]. In addition,
long-circulating nanoparticles can penetrate plaques
through the enlarged cellular gaps within the endothelial
lining and thereby reach intra-plaque components. Nano-
particles can also be functionalized to target molecules or
cells within the plaque, such as oxidized LDL or macro-
phages. The ability to target these processes allows targeted
therapy of atherosclerosis with nanoparticles [8], while
nanoparticles loaded with contrast agents can serve as
imaging reporters [9]. For example, reconstituted high-
density lipoproteins can be incorporated with contrast-
generating materials to enable target-specific imaging of
macrophages in plaques using a variety of imaging
modalities, including MRI and CT [10].
Nanoparticles that hold both therapeutic drugs and
diagnostic labels are popularly referred to as theranostic
nanoparticles. Nevertheless, the field on nanotheranostics is
not solely focused on the use of theranostic nanoparticles,
but also includes a variety of combinations of nano-
medicine, (targeted) therapy, and imaging [11], with the
ultimate aim to improve diagnosis, achieve targeted
therapy, or monitor response to therapy. Due to their
complexity, it is unlikely that theranostic nanoparticles will
be consistently applied clinically. However, nanotheranostic
approaches may have significant benefits. Moreover,
compared to dedicated therapeutic nanoparticles, theranos-
tic nanoparticles provide interesting additional benefits that
can facilitate and speed up preclinical development.
Advantages include the ability to monitor biodistribution
and investigate nanoparticle dynamics in the body over
time [12]. In addition, ex vivo imaging techniques, such as
transmission electron microscopy (TEM) and fluorescence
microscopy, are frequently used for co-localization purpo-
ses and to corroborate in vivo findings. Altogether, nano-
theranostics has the potential to accelerate and improve the
development of novel therapeutic strategies for CVD.
Overview of Studies
Nanotheranostic studies can roughly be classified into three
distinct categories. First, the use of nanoparticulate contrast
agent–aided imaging to evaluate the efficacy of therapy;
second, the use of imaging to evaluate nanotherapy; third,
the use of theranostic nanoparticles for the purpose of
diagnosing, treating, and subsequently evaluating disease
(Fig. 1).
Nanoparticle-Aided Imaging to Evaluate Efficacy
of Therapy
Atherosclerosis
It is well established that ultrasmall particles of iron oxide
(USPIO) are taken up by macrophages in high-risk
atherosclerotic plaques in both animals and humans [13,
14]. Following up on this, Morris et al. [15] used USPIO-
enhanced MRI to evaluate therapeutic effects of a p38
kinase inhibitor, a critical molecule in the immune
response, in an apolipoprotein E–deficient (ApoE KO)
mouse model. The MRI studies revealed decreased accu-
mulation of USPIO in the aortic root and arch area. In
addition, ex vivo histology confirmed that the majority of
USPIO were associated with macrophages. Their findings
indicate the potential of USPIO-enhanced MRI as a method
to evaluate therapeutic effects noninvasively [15]. In
patients, this method has been used to evaluate statin
treatment and the effects of high-dose and a low-dose of
atorvastatin on carotid plaques. Continuation of a high-dose
treatment for 12 weeks decreased USPIO uptake in
carotid plaques, while the low-dose treatment had no
significant effect. This study represents one of the first
clinical examples of nanoparticle-aided noninvasive
imaging for the evaluation of drug therapy in patients
with atherosclerosis [16•].
Fig. 1 Three strategies used in nanotheranostic studies for cardiovascu-
lar disease
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Peripheral artery disease (PAD) refers to luminal
narrowing of peripheral arteries, which subsequently leads
to reduced blood flow and oxygenation of tissue, resulting
in PAD symptoms such as claudication or critical limb
ischemia [17]. L-arginine can increase arteriogenesis, a
biological process that has the potential to decrease PAD
symptoms by increasing blood flow and oxygenation.
Winter et al. [18] applied a nanoparticle formulation, with
a diameter<300 nm, specific to αvβ3-integrin to evaluate if
targeted nanoparticles can detect the neovascular response
to arteriogenic treatment in a rabbit model. Ischemic hind
limbs showed elevated signal enhancement in response to
treatment with in vivo nanoparticle-enhanced MRI
(Fig. 2a), which was corroborated with ex vivo X-ray
angiography. This method might lead to an earlier and more
accurate detection of collateral vessel growth in response to
treatment in PAD patients [18].
Evaluation of Nanotherapy by Imaging
Vascular Injury and Stenosis Inhibition
The luminal narrowing of blood vessels due to atheroscle-
rosis progression is referred to as stenosis. Treating stenotic
vessels with balloon dilatation and stent placement are well-
accepted strategies for revascularization. However, reste-
nosis in dilated and stented vessels may elicit other
complications, such as myocardial damage and impeded
peripheral circulation. Drug-eluting stents can reduce in-
stent restenosis but can also interfere with endothelial
healing, which can cause late-stent thrombosis [19]. Cyrus
et al. [20] developed rapamycin-loaded αvβ3−integrin–
targeted paramagnetic nanoparticles with the purpose of
reducing stenosis after balloon injury without inhibiting
endothelial healing. The nanoparticles, with a diameter of
193 nm, were intramurally injected after balloon injury of
the femoral artery of a rabbit model. MR angiograms were
able to track nanoparticle uptake in injured femoral arteries
in vivo, also showing patent and less stenotic arteries after
2 weeks. These findings were confirmed by histology with
significantly reduced stenosis, while endothelial healing
remained unaffected. This platform could be a potential
alternative to drug-eluting stents or serve as a supplement to
current therapy [20]. Using a different form of focal
therapy, Chorny et al. [21] developed novel paclitaxel-
loaded magnetic nanoparticles (MNPs) that have a diameter
of 263 nm and exploit magnetic properties of stents. By
applying a uniform magnetic field after the administration
of MNPs, they specifically accumulate in stented areas,
achieving a high local concentration of paclitaxel. Fluores-
cence imaging and histology were used to evaluate
therapeutic effects, finding local accumulation of MNPs
that delayed cell proliferation and in-stent restenosis. The
advantages of this system include an improved therapeutic
effect over nanoparticles without the applied magnetic field
and the possibility to adjust local drug concentrations by
controlling the external magnetic field [21].
Peripheral Arterial Disease: Improving Perfusion
Cytokines, such as vascular endothelial growth factor
(VEGF), are potent therapeutic compounds. However, they
exhibit limited circulatory half-life and poor specificity. In a
study by Kim et al. [22], a targeted gold nanoparticle was
developed with a size of 80 nm that specifically delivers
VEGF to ischemic tissue for the purpose of increasing
therapeutic angiogenesis. Laser Doppler perfusion imaging
was used to noninvasively evaluate therapeutic effects. In
this study, VEGF-conjugated gold nanoparticles increased
perfusion of ischemic musculature by 1.7-fold compared to
free VEGF in a murine hind limb model (Fig. 2b) [22]. This
study exemplifies the ability of nanoparticles to increase the
efficacy of certain molecules by increasing their circulatory
half-lives and specificity, while also reducing undesired
side effects.
Limiting Reperfusion Injury in Acute Myocardial Infarction
Adenosine is being investigated as an adjunct to reperfusion
therapy for acute myocardial infarction as it shows
cardioprotective effects in clinical trials [23]. Disadvantages
of adenosine include an extremely short half-life (1 to 2 s)
and the side effects such as hypotension and bradycardia.
Takahama et al. [24] injected a liposomal formulation of
adenosine, with a mean diameter of 134 nm, intravenously
in an ischemic/reperfusion myocardial rat model prior to the
onset of reperfusion. TEM and fluorescence images showed
the accumulation of liposomes in infarcted areas. Liposo-
mal adenosine showed an enhanced circulation time,
reduced side effects, and significantly reduced myocardial
infarction size compared to free adenosine controls [24].
Thrombosis Treatments
Phe[D]-Pro-Arg-Chloromethylketone (PPACK) has a very
specific affinity to thrombin, a key molecule in the
coagulation cascade, and has the potential to be applied as
an anti-thrombotic agent. In a study by Myerson et al. [25],
PPACK molecules were conjugated to perfluorocarbon nano-
particles, with a final size of 160.5 nm. In a photochemical
injury thrombosis mouse model, they showed that the anti-
thrombosis efficacy of PPACK nanoparticles was higher than
free PPACK and heparin, as PPACK nanoparticle–treated
mice developed thrombosis at later time points. Ex vivo
proton MRI and 19F MRI showed that the nanoparticles
specifically accumulated at thrombotic sites [25]. In another
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Fig. 2 Studies that used different nanotheranostic strategies. a, L-
arginine treatment increases arteriogenesis in ischemic tissue. Right
femoral arteries of rabbits were surgically ligated, while the left
femoral arteries served as controls. After ligation rabbits received
10 days’ treatment of L-arginine or tap water and were imaged by
αvβ3-integrin–targeted nanoparticle-aided T1-weighted MRI. Red
color-coded signal enhancement indicates that arteriogenesis is more
prevalent after L-arginine treatment. (Adapted from Winter et al. [18];
with permission.) b, Comparison of perfusion after administration of
VEGF-conjugated gold nanoparticles in ischemic hind limbs. After
ligation of the femoral artery either VEGF-conjugated nanoparticles or
free VEGF was administered. Five weeks post-treatment, VEGF-
conjugated nanoparticle–treated mice have improved blood perfusion
(upper panel) compared to free VEGF-treated mice (lower panel)
shown by laser Doppler perfusion imaging. (Adapted from Kim et al.
[22]; with permission.) c, A single dose of αvβ3 -integrin–targeted
fumagillin-loaded nanoparticle treatment suppresses angiogenesis in
aortic wall. Cardiac magnetic imaging was performed on hyper-
lipidemic rabbits at the moment of nanoparticle treatment (week 0),
and 1, 3, or 4 weeks post-treatment. The red overlays on the arterial
wall are color-coded percentages of signal enhancement. (Adapted
from Winter et al. [30]; with permission.) d, Liposome-encapsulated
glucocorticoids have anti-inflammatory effects on atherosclerotic
plaques of rabbits. Rabbits received a single dose of liposomes and
were imaged by 18F-FDG-PET/CT and DCE-MRI pre and post
treatment. The top two panels show coronal CT, 18F-FDG-PET, and
fused imaging slices of the abdominal aorta pre and 1 week post
treatment. Yellow arrows indicate patchy areas with decreased FDG
uptake after treatment. DCE-MRI shows a decrease in area under the
curve (AUC) 2 days post treatment (right panel) compared to baseline
(left panel). The color overlays on the MRI images are expressed in
percentage of AUC, which has shown to correlate with neovascula-
rization in atherosclerotic arterial walls. (Adapted from Lobatto et al.
[31•]; with permission)
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study, Peters et al. [26] developed a micelle-based theranostic
nanoparticle that can be loaded with anti-coagulation drugs
and peptides that specifically bind to clotted plasma proteins.
The 17-nm nanoparticles showed specific in vivo targeting to
atherosclerotic plaques as shown by ex vivo fluorescence
imaging. When loaded with hirulog, an anti-thrombosis
peptide, the nanoparticles showed better anti-thrombosis
effects than free hirulog at the same molar concentrations
in ApoE KO mice [26].
Theranostic Nanoparticles for Simultaneous Treatment
and Evaluation of Disease
Inhibiting Restenosis
As previously mentioned, restenosis frequently occurs after
revascularization treatment. Smooth muscle cell (SMC)
proliferation in the vessel wall is believed to promote
restenosis and, therefore, inhibition of this process has been
investigated as a strategy to prevent restenosis [27]. In a
study by Lanza et al. [28], perfluorocarbon nanoparticles
were used to deliver doxorubicin and paclitaxel, two potent
anti-proliferation drugs, to SMCs in the arterial wall of
restenotic vessels. The nanoparticles, with a size of 250 nm,
were targeted to tissue factor expressed by SMCs and their
inhibited proliferation was observed in vitro. T1-weighted
MRI detected the uptake of particles while 19F MRI
spectroscopy allowed distinguishing the nanoparticles from
other tissue. Although no in vivo data were shown, this
study exemplifies an interesting theranostic nanoparticle
system for CVD [28].
Stabilizing High-Risk Atherosclerotic Plaques
Inhibiting angiogenesis has been shown to halt the
progression of atherosclerosis [7]. In a study by Winter et
al. [29], αvβ3-integrin targeted paramagnetic nanoparticles
were loaded with the anti-angiogenesis drug fumagillin.
MRI was used to evaluate the response to treatment by
measuring changes in signal enhancement in atherosclerotic
plaques. Decreased signal enhancement was seen after
treatment, which indicated reduced angiogenesis. The in
vivo evaluation was confirmed by ex vivo staining of
microvessels [29]. This is the first study to show the
application of dual-purpose theranostic nanoparticles in
atherosclerosis. In a subsequent study, the theranostic
advantages were further exploited by a combinatory
treatment of anti-angiogenic nanoparticles and oral statins,
which revealed synergistic effects. Using cardiac magnetic
resonance molecular imaging, the therapeutic response
could be evaluated over time (Fig. 2c) [30].
Due to the inflammatory nature of atherosclerotic
plaques, anti-inflammatory drugs such as glucocorticoids
have been proposed as a treatment, though the systemic side
effects impede its application in clinical medicine. Lobatto et
al. [31•] used paramagnetically labeled liposomes, with a
size of 103 nm, as drug carriers to deliver glucocorticoids to
atherosclerotic lesions in order to improve therapeutic
efficacy. T1-weighted MRI showed that liposomes could be
detected in atherosclerotic plaques. To evaluate therapeutic
efficacy, 18F-Fluoro-deoxy-glucose positron emission tomog-
raphy (18F-FDG-PET), a noninvasive imaging modality that
can detect plaque inflammation, showed reduced uptake of
FDG in plaques. Furthermore, dynamic contrast-enhanced
MRI (DCE-MRI), a method for detecting neovascularization,
showed decreased uptake of contrast agents in the arterial
wall (Fig. 2d) [31•].
McCarthy et al. [32] developed a novel theranostic
platform to target macrophages. Dextran-coated iron oxide
nanoparticles were loaded with near-infrared fluorophores
and phototoxic agents and resulted in a particle size of
49.9 nm. The nanoparticles specifically targeted macro-
phages and were activated by light to induce apoptosis in
the targeted macrophages. In an ApoE KO mouse model
the nanoparticles were shown to localize in atherosclerotic
plaques by intravital fluorescence microscopy. Ex vivo
histology staining showed that the nanoparticles induced
massive death of macrophages, while they showed less skin
toxicity than free phototoxic agents [32].
Limitations and Conclusions
Although various nanotheranostic strategies have been
developed and significant advances have been achieved
preclinically, some limitations in the present studies need to
be addressed for future exploration and clinical translation.
Currently, no standardized test procedures are available to
evaluate the quality of nanoparticle therapeutics in general
and their application for CVD specifically [33]. The same
applies to the regulatory aspects. In addition, it is important
to choose a proper disease model to test the efficacy of
those nanoparticles that have shown potential in vitro. For
the purpose of standardization, only well-established animal
models should be used, such as the ApoE KO mouse model
for atherosclerosis. Importantly, the acquired results should
be critically interpreted, because of the differences in the
pathology between animal models and humans. In mice,
atherosclerotic plaques develop much faster and are
smaller, which causes their buildup and function to be
different. Mouse plaques are associated with limited neo-
vascularization, and plaque rupture and thrombosis rarely
occur. In addition, the arterial anatomy of mice is different
from that of humans [34, 35]. Therefore, nanoparticle
studies that display promising results preclinically do not
guarantee their suitability for clinical use. In certain
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theranostic nanoparticle formulations, toxic components are
included, such as gadolinium, for diagnostic purposes [36].
This limits the use of such nanoparticles for long-term or
high-frequency treatment in animal models and excludes their
use in humans. In addition to the explored agents, novel
diagnostic and therapeutic agents, including cleavable
targeted peptides [37] and siRNA [38], are investigated in
cardiovascular disease models and show great diagnostic
and therapeutic potential. To enhance their function, these
agents could be applied as nanoparticle formulations.
Far and foremost, it seems unlikely that theranostic
nanoparticles will be applied to patients on a large scale. As
mentioned before, therapeutic nanoparticles with imaging
labels have several benefits in the developmental phase of
nanotherapy, which may ultimately be stripped down to a
pure therapeutic nanoparticle when moving forward to the
clinic. On the other hand, the use of state-of-the-art
atherosclerosis imaging techniques to evaluate novel ther-
apies has recently been demonstrated in a multicenter
clinical trial [39•]. A similar setup to evaluate anti-
atherosclerotic nanotherapy would be a type of nano-
theranostics that is likely to occur in the near future, while
nanoparticle-enhanced imaging to evaluate traditional ther-
apy has already been reported.
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